

Safety Related Changes

Liver function tests including ALT and total bilirubin should now be monitored every 2 weeks during the first 2 months of treatment with Xalkori (**crizotinib**), then once a month and as clinically indicated, with more frequent repeat testing for grades 2, 3 or 4 elevations.

Xgeva (**denosumab (rch)**) is now contraindicated in severe untreated hypocalcaemia.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.